ACETYLCYSTEINE

Post-LOE

acetylcysteine

ANDAINTRAVENOUSINJECTABLE
Approved
Nov 2012
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
19

Mechanism of Action

Reduction Activity

Pharmacologic Class:

Antidote

Clinical Trials (5)

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Started Sep 2024
0
Common Cold
NCT05241262Phase 1Recruiting

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Started Jul 2023
18 enrolled
Mitochondrial Disease
NCT04481048Phase 2Active Not Recruiting

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Started Dec 2020
58 enrolled
Neurofibromatosis 1
NCT04123405Phase 3Completed

Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis

Started Oct 2020
944 enrolled
Rhinosinusitis
NCT04419025Phase 2Completed

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Started Sep 2020
165 enrolled
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere+1 more